openPR Logo
Press release

Hearing Loss Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos

03-31-2025 03:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Hearing Loss Pipeline 2025: Latest FDA Approvals, Clinical

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hearing Loss pipeline constitutes 32+ key companies continuously working towards developing 35+ Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hearing Loss Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hearing Loss Market.

The Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hearing Loss Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Hearing Loss treatment therapies with a considerable amount of success over the years.

*
Hearing Loss companies working in the treatment market are Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others, are developing therapies for the Hearing Loss treatment

*
Emerging Hearing Loss therapies in the different phases of clinical trials are- ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others are expected to have a significant impact on the Hearing Loss market in the coming years.

*
In February 2025, Sound Pharmaceuticals is excited to share that it will deliver four presentations at the upcoming Association for Research in Otolaryngology MidWinter Meeting. One of the key presentations, titled "The Development of SPI-1005 for the Treatment of Hearing Loss and Tinnitus," will be featured at the Pharmaceutical Interventions for Hearing Loss (PIHL) Satellite Symposium. Organized by the Defense Health Agency (DHA) Hearing Center of Excellence (HCE) committee, this symposium will offer an in-depth review of investigational treatments aimed at preventing hearing loss and promoting hearing restoration.

*
In January 2025, US-based dermatology biopharma Eirion Therapeutics reported positive findings from its first-in-human, double-blind, placebo-controlled study of its topical treatment for age-related hair loss, demonstrating a six-fold increase in hair count over placebo. ET-02, the company's most advanced therapy for androgenic alopecia, was evaluated in a trial involving 24 male patients across three US sites, successfully meeting its primary safety and tolerability endpoints. Additionally, Eirion Therapeutics is advancing a preclinical oral version of ET-02, further expanding its pipeline for hair loss treatments.

*
In August 2024, Pelage Pharmaceuticals, a clinical-stage company specializing in regenerative medicine for hair loss, commenced its Phase 2a clinical trial for PP405, a novel topical small molecule aimed at treating androgenetic alopecia (pattern baldness). The first patients have been dosed, and the study will evaluate the drug's safety and effectiveness. The trial plans to enroll 60 men and women, with PP405 designed to activate dormant hair follicle stem cells, promoting hair growth

Hearing Loss Overview

Hearing Loss (SNHL) occurs due to damage to inner ear structures or the auditory nerve. It accounts for over 90 percent of hearing impairment in adults. Typical causes of SNHL include prolonged exposure to loud noises, genetic predisposition, or the natural aging process.

Get a Free Sample PDF Report to know more about Hearing Loss Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hearing-loss-pipeline-insight [https://www.delveinsight.com/report-store/hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Hearing Loss Drugs Under Different Phases of Clinical Development Include:

ACOU085: Acousia Therapeutics

*
Cochlear Hair Cell Regeneration: Decibel Therapeutics

*
HY01: Suzhou Pharmaceutical Technology Co.,Ltd

*
AC102: AudioCure Pharma GmbH

*
SENS-401: Sensorion

Hearing Loss Route of Administration

Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Ophthalmic

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Hearing Loss Molecule Type

Hearing Loss Products have been categorized under various Molecule types, such as

*
Products have been categorized under various Molecule types such as

*
Oligonucleotide

*
Peptide

*
Small molecule

Hearing Loss Pipeline Therapeutics Assessment

*
Hearing Loss Assessment by Product Type

*
Hearing Loss By Stage and Product Type

*
Hearing Loss Assessment by Route of Administration

*
Hearing Loss By Stage and Route of Administration

*
Hearing Loss Assessment by Molecule Type

*
Hearing Loss by Stage and Molecule Type

DelveInsight's Hearing Loss Report covers around 35+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Hearing Loss product details are provided in the report. Download the Hearing Loss pipeline report to learn more about the emerging Hearing Loss therapies [https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Hearing Loss Therapeutics Market include:

Key companies developing therapies for Hearing Loss are - Sensorion, Fennec Pharmaceuticals, Sound Pharmaceuticals, Decibel Therapeutics, Akouos, and others.

Hearing Loss Pipeline Analysis:

The Hearing Loss pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Hearing Loss with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hearing Loss Treatment.

*
Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hearing Loss market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hearing Loss drugs and therapies [https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hearing Loss Pipeline Market Drivers

*
Rise in the Incidence of Hearing Loss, rising Awareness and Initiatives about Hearing loss are some of the important factors that are fueling the Hearing Loss Market.

Hearing Loss Pipeline Market Barriers

*
However, high Cost of treatment, presence of Substitute Products and other factors are creating obstacles in the Hearing Loss Market growth.

Scope of Hearing Loss Pipeline Drug Insight

*
Coverage: Global

*
Key Hearing Loss Companies: Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others

*
Key Hearing Loss Therapies: ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others

*
Hearing Loss Therapeutic Assessment: Hearing Loss current marketed and Hearing Loss emerging therapies

*
Hearing Loss Market Dynamics: Hearing Loss market drivers and Hearing Loss market barriers

Request for Sample PDF Report for Hearing Loss Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/hearing-loss-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hearing Loss Report Introduction

2. Hearing Loss Executive Summary

3. Hearing Loss Overview

4. Hearing Loss- Analytical Perspective In-depth Commercial Assessment

5. Hearing Loss Pipeline Therapeutics

6. Hearing Loss Late Stage Products (Phase II/III)

7. Hearing Loss Mid Stage Products (Phase II)

8. Hearing Loss Early Stage Products (Phase I)

9. Hearing Loss Preclinical Stage Products

10. Hearing Loss Therapeutics Assessment

11. Hearing Loss Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hearing Loss Key Companies

14. Hearing Loss Key Products

15. Hearing Loss Unmet Needs

16 . Hearing Loss Market Drivers and Barriers

17. Hearing Loss Future Perspectives and Conclusion

18. Hearing Loss Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hearing-loss-pipeline-2025-latest-fda-approvals-clinical-trials-and-emerging-therapies-assessment-by-delveinsight-sensorion-fennec-pharma-sound-pharma-decibel-therapeutics-akouos]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hearing Loss Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos here

News-ID: 3947633 • Views:

More Releases from ABNewswire

Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Tr …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Alopecia Areata pipeline constitutes 18+ key companies continuously working towards developing 20+ Alopecia Areata treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Alopecia Areata Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed
Paws and Passport Launches 'My Little Love,' a Heartwarming Tribute to Pet Parenthood
Paws and Passport Launches 'My Little Love,' a Heartwarming Tribute to Pet Paren …
California, USA - May 01, 2025 - Paws and Passport, LLC, an organization working to empower pet parents, has announced the release of its debut book, "My Little Love" [http://www.amazon.com/dp/B0DQH3SSS2]. This nonfiction tribute reflects the unconditional bond between pets and their owners in terms of much-needed joys, including issues and the remarkable love shared with animal companions. As the first release by Paws and Passport, "My Little Love" [http://www.amazon.com/dp/B0DQH3SSS2] underlines the
Stanley Howard Freeman Unveils Comprehensive Guide to Understanding Cancer in His Latest Book
Stanley Howard Freeman Unveils Comprehensive Guide to Understanding Cancer in Hi …
Stanley Howard Freeman's latest work, "27 Cancers [https://www.amazon.com/Cancers-DR-stanley-Howard-Freeman/dp/B0DW92CMWN]," delivers a complete overview of many types of cancer, intending to educate and empower readers. As medical developments grow quickly, this book is a vital source for the general public and healthcare professionals. With a pleasing writing style, Freeman digs into 27 distinct forms of cancer, providing an understanding of their causes, symptoms, diagnostic methods, treatment options, and protective measures. Stanley Howard Freeman
Beta Thalassemia Market Set to Grow Substantially Through 2034, DelveInsight Projects | Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma, Acceleron Pharma, Bristol-Myers
Beta Thalassemia Market Set to Grow Substantially Through 2034, DelveInsight Pro …
The Key Beta Thalassemia Companies in the market include - Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others. DelveInsight's "Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Beta Thalassemia, historical and forecasted epidemiology as well as the Beta Thalassemia market trends in the

All 5 Releases


More Releases for Hearing

Hearing is Believing: Precision Implantation of Cutting-Edge Hybrid Hearing Devi …
Study by Karl Landsteiner University of Health Sciences in Krems demonstrates long-term effectiveness of electric-acoustic stimulation as a treatment for hearing impairment Krems, Austria, 13. August 2020 – Precision surgical implantation of electrodes for the electric-acoustic stimulation of the inner ear can stabilise the long-term residual hearing of severely hearing-impaired people and significantly improve their speech recognition. These are the findings of a study carried out by Karl Landsteiner University of
Global Wireless Hearing Aid Market Driving Future Growth on Wireless Hearing Aid …
Global Wireless Hearing Aid Market 2025: Global Wireless Hearing Aid Industry Market professional research 2015-2025, is a report which provides the details about industry overview, industry chain, market size (sales, revenue, and growth rate), gross margin, major manufacturers, development trends and forecast. PDF Copy Available at Disconted Price Check Discount @ https://www.marketgrowthinsight.com/discount/90344 The Global Wireless Hearing Aid Market will reach xxx Million USD in 2020 with CAGR xx% 2020-2025. The objective of
Smart Hearing Aids Market Development Insight and Manufacturers Challenges By Ke …
Recent research and the current scenario as well as future market potential of "Global Smart Hearing Aids Market Professional Survey Report 2019". The Smart Hearing Aids Market comprehensively describes the market and prognosticates it to depict a highly illustrious growth during the forthcoming years. The report offers in-depth analysis of current and future Smart Hearing Aids Market outlook across the globe. The report is projected to help readers with the regions
2019 Hearing Aid Market– Sivantos, Starkey, Benson Hearing, ReSound Group, Mic …
Researchmoz added Most up-to-date research on "Global Hearing Aid Market Insights, Forecast to 2025" to its huge collection of research reports. Hearing Aid Market report includes (6 Year Forecast 2019-2025) includes Overview, classification, industry value, price, cost and gross profit. It also offers in-intensity insight of the Hearing Aid industry masking all vital parameters along with, Drivers, Market Trends, Market Dynamics, Opportunities, Competitive Landscape, Price and Gross Margin, Hearing Aid market
Hearing Aid Market 2018 Global Analysis of Key Players – SONOVA , COCHLEAR , W …
Global hearing aid market to reach USD 12.1 billion by 2025. Global hearing aid market is valued at approximately USD 7.0 billion in 2017 and is anticipated to grow with a healthy growth rate of more than 7.0 % over the forecast period 2018-2025. Key trends for the global hearing aids market are technological advancements such as noise reduction circuits, wireless and bluetooth technology and feedback reduction, aesthetically appealing miniature devices.
Power for hearing intelligence: HANSATON launches beat SHD power hearing system …
HANSATON presents the beat SHD product family, its most powerful behind-the-ear hearing systems with SHD technology for significant hearing loss Hamburg, October 1, 2018: With the two behind-the-ear hearing systems in its beat SHD product family, the Hamburg-based hearing system manufacturers at HANSATON have developed their most powerful SHD technology-based hearing systems yet—especially for users with significant to profound hearing loss. Like all of HANSATON’s hearing systems with SHD technology,